Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations

被引:51
作者
Isik, FF
Rand, RP
Gruss, JS
Benjamin, D
Alpers, CE
机构
[1] UNIV WASHINGTON,MED CTR,DEPT PATHOL,SEATTLE,WA 98195
[2] CHILDRENS HOSP,DEPT PATHOL,SEATTLE,WA 98195
关键词
D O I
10.1006/jsre.1996.0083
中图分类号
R61 [外科手术学];
学科分类号
摘要
Hemangiomas are vascular tumors that appear at or shortly after birth and undergo a rapid growth before involuting. During the proliferative phase, hemangiomas are infiltrated by macrophages, cells that are capable of initiating angiogenesis. Vascular malformations grow slowly, commensurate with the child, and do not regress or become infiltrated by macrophages. We demonstrate by in situ hybridization increased monocyte chemoattractant protein-1 (MCP-1) mRNA expression during hemangioma and vascular malformation growth. We found markedly upregulated expression of MCP-1 mRNA in all proliferative hemangioma specimens, expressed by alpha-actin(+) perivascular smooth muscle cells and interstitial HAM 56(+) macrophages. In contrast, 9 of 10 clinically involuting hemangiomas displayed no expression of MCP-1 mRNA. We found no expression of MCP-1 mRNA in vascular malformations, which correlates with the minimal monocytic infiltration of these lesions. We also showed that dexamethasone and interferon-cu downregulate MCP-1 mRNA in cultured human vascular smooth muscle cells. Glucocorticoids can be efficacious in 30-50% of cases when given in the proliferative phase of hemangioma growth, but have no beneficial effect on vascular malformations. Interferon-a has been used to dramatically induce regression of steroid-refractory hemangiomas. Both of these agents' beneficial action on proliferative hemangiomas may, in part, result from reduced MCP-1 production and reduced influx of angiogenic macrophages. (C) 1996 Academic Press, Inc.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 29 条
[1]
Adams D O, 1992, INFLAMMATION BASIC P, P645
[2]
CYCLIN PCNA IS THE AUXILIARY PROTEIN OF DNA POLYMERASE-DELTA [J].
BRAVO, R ;
FRANK, R ;
BLUNDELL, PA ;
MACDONALDBRAVO, H .
NATURE, 1987, 326 (6112) :515-517
[3]
INHIBITION OF CELL MOTILITY BY INTERFERON [J].
BROUTYBOYE, D ;
ZETTER, BR .
SCIENCE, 1980, 208 (4443) :516-518
[4]
MONOCLONAL-ANTIBODY TO A HUMAN LEUKOCYTE-SPECIFIC MEMBRANE GLYCOPROTEIN PROBABLY HOMOLOGOUS TO THE LEUKOCYTE-COMMON (L-C) ANTIGEN OF THE RAT [J].
DALCHAU, R ;
KIRKLEY, J ;
FABRE, JW .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1980, 10 (10) :737-744
[5]
ALPHA-SMOOTH MUSCLE ACTIN IS EXPRESSED IN A SUBPOPULATION OF CULTURED AND CLONED FIBROBLASTS AND IS MODULATED BY GAMMA-INTERFERON [J].
DESMOULIERE, A ;
RUBBIABRANDT, L ;
ABDIU, A ;
WALZ, T ;
MACIEIRACOELHO, A ;
GABBIANI, G .
EXPERIMENTAL CELL RESEARCH, 1992, 201 (01) :64-73
[6]
INTERFERON ALFA-2A THERAPY FOR LIFE-THREATENING HEMANGIOMAS OF INFANCY [J].
EZEKOWITZ, RAB ;
MULLIKEN, JB ;
FOLKMAN, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (22) :1456-1463
[7]
BASIC FIBROBLAST GROWTH-FACTOR IN THE EARLY HUMAN BURN WOUND [J].
GIBRAN, NS ;
ISIK, FF ;
HEIMBACH, DM ;
GORDON, D .
JOURNAL OF SURGICAL RESEARCH, 1994, 56 (03) :226-234
[8]
GILMAN M, 1993, PREPARATION RNA EUKA
[9]
GOWN AM, 1986, AM J PATHOL, V125, P191
[10]
HOLTHOFER H, 1982, LAB INVEST, V47, P60